Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Hepatitis

Free Subscription Articles published in J Viral Hepat Retrieve available abstracts of 278 articles: HTML format

Single Articles

April 2023
1. SANDMANN L, Deterding K, Bremer B, Port K, et al
   Kinetics and predictive value of HBcrAg, HBV RNA and anti-HBc during bulevirtide treatment of chronic HDV-infected patients.
   J Viral Hepat. 2023;30:283-286.
   PubMed     Abstract available
   
   
   March 2023
2. HIBBERT M, Simmons R, Harris H, Desai M, et al
   Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England.
   J Viral Hepat. 2023 Mar 17. doi: 10.1111/jvh.13835.
   PubMed     Abstract available
   
   
   
3. DETERDING K, Xu CJ, Port K, Dietz-Fricke C, et al
   Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA.
   J Viral Hepat. 2023 Mar 16. doi: 10.1111/jvh.13831.
   PubMed     Abstract available
   
   
   
4. URAZ S, Deniz Z, Zerdali EY, Araslanova A, et al
   The Changing Epidemiology of Delta Hepatitis in Turkiye over Three Decades: A Systematic Review.
   J Viral Hepat. 2023 Mar 15. doi: 10.1111/jvh.13834.
   PubMed     Abstract available
   
   
   
5. WU C, Xie J, Liu F
   Incidence and factors influencing sleep disorders in patients with chronic hepatitis B infection: A case-control study.
   J Viral Hepat. 2023 Mar 15. doi: 10.1111/jvh.13832.
   PubMed     Abstract available
   
   
   
6. MOREAU C, Roux M, Riou J, Canivet CM, et al
   Dynamic Personalized Prediction of the Individual Liver-Related Risk after Sustained Viral Response in HCV patients.
   J Viral Hepat. 2023 Mar 9. doi: 10.1111/jvh.13830.
   PubMed     Abstract available
   
   
   
7. QIU L, Xu S, Qiu Y, Liu Y, et al
   Comparison of acknowledged hepatocellular carcinoma risk scores in high risk hepatitis C patients with sustained virologic response.
   J Viral Hepat. 2023 Mar 8. doi: 10.1111/jvh.13829.
   PubMed     Abstract available
   
   
   
8. MOONEYHAN E, De la Torre Rosas A, Serrano DB, Gamkrelidze I, et al
   Cost-effectiveness and economic investment to eliminate chronic hepatitis C in Mexico.
   J Viral Hepat. 2023 Mar 8. doi: 10.1111/jvh.13828.
   PubMed     Abstract available
   
   
   
9. SELIM R, Zhou Y, Gordon SC, Zhang T, et al
   Impact of hepatitis C treatment status on risk of Parkinson's disease and secondary parkinsonism in the era of direct-acting antivirals.
   J Viral Hepat. 2023 Mar 5. doi: 10.1111/jvh.13826.
   PubMed     Abstract available
   
   
   
10. ISAEVA OV, Kyuregyan KK, Karlsen AA, Kuzmin OV, et al
    Silent HDV epidemics culminates in high levels of liver cirrhosis in endemic region despite 20 years of HBV vaccination.
    J Viral Hepat. 2023;30:182-194.
    PubMed     Abstract available
    
    
    
11. SULKOWSKI MS
    Hepatitis D virus infection: Progress on the path toward disease control and cure.
    J Viral Hepat. 2023 Mar 1. doi: 10.1111/jvh.13825.
    PubMed    
    
    
    February 2023
12. SHAH SHBU, Alavi M, Hajarizadeh B, Matthews G, et al
    Liver-related mortality among people with hepatitis B and C: evaluation of definitions based on linked healthcare administrative datasets.
    J Viral Hepat. 2023 Feb 27. doi: 10.1111/jvh.13824.
    PubMed     Abstract available
    
    
    
13. WONG RJ, Rupp L, Lu M, Yang Z, et al
    Prevalence of Hepatitis B Virus (HBV) and Latent Tuberculosis Co-Infection and Risk of Drug-Induced Liver Injury Across Two Large HBV Cohorts in the United States.
    J Viral Hepat. 2023 Feb 26. doi: 10.1111/jvh.13823.
    PubMed     Abstract available
    
    
    
14. ANDANI A, Bunge E, Kassianos G, Eeuwijk J, et al
    Hepatitis A Occurrence and Outbreaks in Europe Over the Past Two Decades: a Systematic Review.
    J Viral Hepat. 2023 Feb 24. doi: 10.1111/jvh.13821.
    PubMed     Abstract available
    
    
    
15. MICAELA M, Elizalde MM, Giadans C, Monzani C, et al
    Different mutation rates in the basal core promoter and precore regions between hepatitis B virus subgenotype F1b clusters.
    J Viral Hepat. 2023 Feb 24. doi: 10.1111/jvh.13822.
    PubMed    
    
    
    
16. BRITO WI, Oliveira RM, Silva J, Tubarao LN, et al
    Persistence of immunity against hepatitis A in Brazilian children vaccinated with a single dose of inactivated virus vaccine.
    J Viral Hepat. 2023 Feb 20. doi: 10.1111/jvh.13819.
    PubMed     Abstract available
    
    
    
17. ZHOU Y, Zhao B, Shi W, Ding X, et al
    The infection rates of HBV and HCV decreased significantly in Zhejiang Province, China: a comparative study based on the data of two sero-epidemiological surveys in 1992 and 2020.
    J Viral Hepat. 2023 Feb 20. doi: 10.1111/jvh.13820.
    PubMed     Abstract available
    
    
    
18. ROSSOTTI R, Merli M, Baiguera C, Bana NB, et al
    Impact of treatment with direct-acting antivirals on inflammatory markers and autoantibodies in HIV/HCV co-infected individuals.
    J Viral Hepat. 2023 Feb 11. doi: 10.1111/jvh.13818.
    PubMed     Abstract available
    
    
    
19. SUN F, Wei X, Yaoling O
    Research progress on detection methods for hepatitis B virus covalently closed circular DNA.
    J Viral Hepat. 2023 Feb 8. doi: 10.1111/jvh.13817.
    PubMed     Abstract available
    
    
    
20. HAMILTON EM, Rassam W, Yan Y, Singh A, et al
    Correlates of chronic hepatitis B virus infection in the general adult population of China: systematic review and meta-analysis.
    J Viral Hepat. 2023 Feb 8. doi: 10.1111/jvh.13816.
    PubMed     Abstract available
    
    
    
21. NYAMA ET, Allan-Blitz LT, Bitwayiki R, Swaray M, et al
    Challenges of Hepatitis B Treatment in Rural Sub-Saharan Africa: Treatment Initiation and Outcomes from a Public Hospital-Based Clinic in Kono, Sierra Leone.
    J Viral Hepat. 2023 Feb 5. doi: 10.1111/jvh.13812.
    PubMed     Abstract available
    
    
    
22. FERRAIOLI G
    Interpreting shear wave elastography results in chronic hepatitis D virus infection.
    J Viral Hepat. 2023 Feb 5. doi: 10.1111/jvh.13815.
    PubMed    
    
    
    
23. YARDENI D, Yang AH, Heller T, Koh C, et al
    Reply to "Interpreting shear wave elastography results in chronic hepatitis D virus infection".
    J Viral Hepat. 2023 Feb 5. doi: 10.1111/jvh.13813.
    PubMed    
    
    
    
24. DEGASPERI E, Anolli MP, Lampertico P
    Bulevirtide-based treatment strategies for chronic hepatitis delta: A review.
    J Viral Hepat. 2023 Feb 5. doi: 10.1111/jvh.13811.
    PubMed     Abstract available
    
    
    January 2023
25. FEI Y, Wang Z, Huang M, Wu X, et al
    MiR-155 regulates M2 polarization of hepatitis B virus-infected tumor-associated macrophages which in turn regulates malignant progression of hepatocellular carcinoma.
    J Viral Hepat. 2023 Jan 26. doi: 10.1111/jvh.13809.
    PubMed     Abstract available
    
    
    
26. WANG J, Huang R, Liu J, Lai R, et al
    A novel non-invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD.
    J Viral Hepat. 2023 Jan 25. doi: 10.1111/jvh.13808.
    PubMed     Abstract available
    
    
    
27. TERRAULT NA, Slepin J, Kanner R, Gailloux K, et al
    Strategies to Increase Primary Care Provider Capacity for Hepatitis C Care: The California ECHO-PLUS Study.
    J Viral Hepat. 2023 Jan 25. doi: 10.1111/jvh.13807.
    PubMed     Abstract available
    
    
    
28. LIAN M, Wang Q, Chen S, Yang Y, et al
    The association of serum immunoglobulin and complement levels and liver fibrosis and inflammation stage in patients with chronic hepatitis B.
    J Viral Hepat. 2023 Jan 25. doi: 10.1111/jvh.13810.
    PubMed     Abstract available
    
    
    
29. HUDSON-BUHAGIAR J, Carson J, Monaghan S, Collie P, et al
    Effectiveness of direct-acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: a national real-world cohort (REACH-C).
    J Viral Hepat. 2023 Jan 18. doi: 10.1111/jvh.13803.
    PubMed     Abstract available
    
    
    
30. KALKAN C, Yilmaz Y, Doganay Erdogan B, Savas B, et al
    Non-invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta.
    J Viral Hepat. 2023 Jan 18. doi: 10.1111/jvh.13806.
    PubMed     Abstract available
    
    
    
31. MOONEYHAN E, Qureshi H, Mahmood H, Tariq M, et al
    Hepatitis C prevalence and elimination planning in Pakistan, a bottom-up approach accounting for provincial variation.
    J Viral Hepat. 2023 Jan 17. doi: 10.1111/jvh.13802.
    PubMed     Abstract available
    
    
    
32. KEITOKU T, Tamaki N, Kurosaki M, Inada K, et al
    Effect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapy.
    J Viral Hepat. 2023 Jan 17. doi: 10.1111/jvh.13805.
    PubMed     Abstract available
    
    
    
33. MCKEEVER A, O'Donovan D, Kee F
    Factors influencing compliance with Hepatitis C treatment in patients transitioning from prison to community - a Summary Scoping Review.
    J Viral Hepat. 2023 Jan 12. doi: 10.1111/jvh.13801.
    PubMed     Abstract available
    
    
    
34. KUSHNER T
    Delta Hepatitis Epidemiology and the Global Burden of Disease.
    J Viral Hepat. 2023 Jan 10. doi: 10.1111/jvh.13797.
    PubMed    
    
    
    
35. LEOW YW, Chan WK, Goh GB, Wong VW, et al
    Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: the multicentre, prospective CAP-Asia study.
    J Viral Hepat. 2023 Jan 6. doi: 10.1111/jvh.13796.
    PubMed     Abstract available
    
    
    
36. YOUNOSSI ZM, Yu ML, Yilmaz Y, Alswat KA, et al
    Clinical and Patient-Reported Outcome Profile of Patients with Hepatitis B Viral Infection from the Global Liver Registry.
    J Viral Hepat. 2023 Jan 4. doi: 10.1111/jvh.13800.
    PubMed     Abstract available
    
    
    
37. DEBETTE-GRATIEN M, Francois S, Chevalier C, Alain S, et al
    Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days.
    J Viral Hepat. 2023 Jan 3. doi: 10.1111/jvh.13798.
    PubMed     Abstract available
    
    
    December 2022
38. KOZUKA R, Tamori A, Enomoto M, Muto-Yukawa Y, et al
    Risk Factors for Liver-Related and Non-Liver-Related Mortality following a Sustained Virological Response after Direct-Acting Antiviral Treatment for Hepatitis C Virus Infection in a Real-World Cohort.
    J Viral Hepat. 2022 Dec 30. doi: 10.1111/jvh.13795.
    PubMed     Abstract available
    
    
    
39. UCHIDA T, Yuji T, Imamura M, Abe-Chayama H, et al
    A novel cDNA-uPA/SCID/Rag2(-/-) /Jak3(-/-) mouse model for hepatitis virus infection and reconstruction of human immune system.
    J Viral Hepat. 2022 Dec 27. doi: 10.1111/jvh.13793.
    PubMed     Abstract available
    
    
    
40. YOUSAFZAI MT, Alavi M, Valerio H, Hajarizadeh B, et al
    Hepatitis C care cascade before and during the direct acting antiviral eras in New South Wales, Australia: a population-based linkage study.
    J Viral Hepat. 2022 Dec 19. doi: 10.1111/jvh.13791.
    PubMed     Abstract available
    
    
    
41. BIAN D, Zhao J, Liao H, Wang Y, et al
    Serum HBV RNA is Associated with Liver Fibrosis Regression in HBeAg-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogues.
    J Viral Hepat. 2022 Dec 19. doi: 10.1111/jvh.13790.
    PubMed     Abstract available
    
    
    
42. SIEGELE-BROWN C, Siegele-Brown M, Cook C, Khakoo SI, et al
    Testing to sustain Hepatitis C elimination targets in people who inject drugs: a network-based model.
    J Viral Hepat. 2022 Dec 18. doi: 10.1111/jvh.13786.
    PubMed     Abstract available
    
    
    
43. CAO X, Hu Q, Xu W, Li Q, et al
    Kinetics changes in total cholesterol predict HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon-alfa.
    J Viral Hepat. 2022 Dec 18. doi: 10.1111/jvh.13787.
    PubMed     Abstract available
    
    
    
44. LAM L, Fontaine H, Lapidus N, Bellet J, et al
    Performance of Algorithms for Identifying Patients With Chronic Hepatitis B or C Infection in the French Health Insurance Claims Databases Using the ANRS CO22 HEPATHER Cohort.
    J Viral Hepat. 2022 Dec 18. doi: 10.1111/jvh.13788.
    PubMed     Abstract available
    
    
    
45. GILL US
    The immune landscape in Hepatitis Delta Virus Infection - still an open field!
    J Viral Hepat. 2022 Dec 18. doi: 10.1111/jvh.13785.
    PubMed     Abstract available
    
    
    
46. TARIK A
    Beyond bulevirtide: Alternative therapeutic options for the management of hepatitis delta virus.
    J Viral Hepat. 2022 Dec 18. doi: 10.1111/jvh.13789.
    PubMed     Abstract available
    
    
    
47. CHAK EW, Luna R, MacDonald S, Stewart SL, et al
    Automated Electronic Health Registry-Based Hepatitis B Screening.
    J Viral Hepat. 2022 Dec 14. doi: 10.1111/jvh.13784.
    PubMed     Abstract available
    
    
    
48. SARACCO M, Tandoi F, Maletta F, Balagna R, et al
    Early post-liver transplant use of direct-acting antivirals in naive and NS5A inhibitor-experienced HCV patients.
    J Viral Hepat. 2022 Dec 7. doi: 10.1111/jvh.13782.
    PubMed     Abstract available
    
    
    
49. ROHRIG AM, Jakobi K, Dietz J, Thomas D, et al
    The Role of Serum Sphingolipids as potential biomarkers of non-response to Direct Acting Antiviral-Therapy in Chronic Hepatitis C Virus Infection.
    J Viral Hepat. 2022 Dec 4. doi: 10.1111/jvh.13776.
    PubMed     Abstract available
    
    
    
50. GREENWALD ZR, Bouck Z, McLean E, Mason K, et al
    Integrated supervised consumption services and hepatitis C testing and treatment among people who inject drugs in Toronto, Canada: a cross-sectional analysis.
    J Viral Hepat. 2022 Dec 3. doi: 10.1111/jvh.13780.
    PubMed     Abstract available
    
    
    
51. NATHANI R, Leibowitz R, Giri D, Villarroel C, et al
    The Delta Delta: Gaps in Screening and Patient Assessment for Hepatitis D Virus Infection.
    J Viral Hepat. 2022 Dec 2. doi: 10.1111/jvh.13779.
    PubMed     Abstract available
    
    
    
52. MUTIMER D, Elsharkawy A, Hathorn E, Arunkumar S, et al
    Age, ethnicity and proximity to clinic determine retention in care of chronic hepatitis B patients.
    J Viral Hepat. 2022 Dec 2. doi: 10.1111/jvh.13775.
    PubMed     Abstract available
    
    
    
53. KOFFAS A, Mak LY, Kennedy PTF
    Hepatitis delta virus: Disease assessment and stratification.
    J Viral Hepat. 2022 Dec 2. doi: 10.1111/jvh.13777.
    PubMed     Abstract available
    
    
    
54. ABDELHAMED W, El-Kassas M
    Hepatocellular Carcinoma and Hepatitis C Virus Treatments: The Bold and The Beautiful.
    J Viral Hepat. 2022 Dec 2. doi: 10.1111/jvh.13778.
    PubMed     Abstract available
    
    
    
55. FELD JJ, Forns X, Dylla DE, Kumada H, et al
    Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohorts.
    J Viral Hepat. 2022;29:1050-1061.
    PubMed     Abstract available
    
    
    November 2022
56. HYDE Z, Roura R, Signer D, Patel A, et al
    Evaluation of a Pilot Emergency Department Linkage to Care Program for Patients Previously Diagnosed with Hepatitis C.
    J Viral Hepat. 2022 Nov 28. doi: 10.1111/jvh.13774.
    PubMed     Abstract available
    
    
    
57. PERAZZO H, Silva MST, Coutinho C, Peixoto EM, et al
    Monkeypox outbreak as an opportunity to identify new cases of HCV infection in limited resource settings.
    J Viral Hepat. 2022 Nov 10. doi: 10.1111/jvh.13771.
    PubMed    
    
    
    
58. LEE C, Emeto TI, Walsh N
    Prevalence of hepatitis B virus amongst refugees, asylum seekers and internally displaced persons in low- and middle-income countries: a systematic review.
    J Viral Hepat. 2022 Nov 10. doi: 10.1111/jvh.13770.
    PubMed     Abstract available
    
    
    
59. LI G, Zhang P, Zhu Y
    Artificial liver support systems for hepatitis B virus-associated acute-on-chronic liver failure: A meta-analysis of the clinical literature.
    J Viral Hepat. 2022 Nov 3. doi: 10.1111/jvh.13767.
    PubMed     Abstract available
    
    
    
60. GIRI S, Agrawal D, Afzalpurkar S, Gopan A, et al
    Tenofovir Versus Entecavir for Tertiary Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B Infection After Curative Therapy: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2022 Nov 2. doi: 10.1111/jvh.13766.
    PubMed     Abstract available
    
    
    
61. HWANG SY, Yoo SH, Chang HY, Kim S, et al
    Baseline and on-treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals.
    J Viral Hepat. 2022 Nov 2. doi: 10.1111/jvh.13765.
    PubMed     Abstract available
    
    
    October 2022
62. BITTENCOURT PL, Iasi MDSF, Viana MV, Crespo DM, et al
    Poor linkage to care may compromise the brazilian plan for hepatitis c elimination.
    J Viral Hepat. 2022 Oct 27. doi: 10.1111/jvh.13762.
    PubMed     Abstract available
    
    
    
63. CASEY JL, Dore GJ, Grebely J, Matthews GV, et al
    Hepatitis C Virus-Specific Immune Responses Following Direct Acting Antivirals Administered During Recent Hepatitis C Virus Infection.
    J Viral Hepat. 2022 Oct 27. doi: 10.1111/jvh.13761.
    PubMed     Abstract available
    
    
    
64. AGARWAL K, Xu J, Gane EJ, Nguyen TT, et al
    Safety, pharmacokinetics, and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor: a randomized, placebo-controlled Phase 1 study.
    J Viral Hepat. 2022 Oct 27. doi: 10.1111/jvh.13764.
    PubMed     Abstract available
    
    
    
65. CHADHA N, Turner A, Sterling RK
    Prevalence and predictors of abnormal alanine aminotransferase in patients with HCV who have achieved SVR.
    J Viral Hepat. 2022 Oct 27. doi: 10.1111/jvh.13763.
    PubMed     Abstract available
    
    
    
66. SALPINI R, D'Anna S, Piermatteo L, Svicher V, et al
    Novel concepts on mechanisms underlying Hepatitis Delta virus persistence and related pathogenesis.
    J Viral Hepat. 2022 Oct 18. doi: 10.1111/jvh.13755.
    PubMed     Abstract available
    
    
    
67. SQUIRES KE, Ogilvie L, Jucov A, Anastasiy I, et al
    A Randomized Phase 1b Trial of the Active Site Polymerase Inhibitor Nucleotide ATI-2173 in Patients With Chronic Hepatitis B Virus Infection.
    J Viral Hepat. 2022 Oct 6. doi: 10.1111/jvh.13753.
    PubMed     Abstract available
    
    
    
68. HALL EW, Gounder P, Angles J, Nelson NP, et al
    Evaluating the Cost-Effectiveness of Hepatitis B Vaccination Strategies in High-impact Settings for Adults.
    J Viral Hepat. 2022 Oct 6. doi: 10.1111/jvh.13759.
    PubMed     Abstract available
    
    
    
69. HEO M, Pericot-Valverde I, Niu J, Norton BL, et al
    More intensive hepatitis C virus care models promote adherence among people who inject drugs with active drug use: The PREVAIL Study.
    J Viral Hepat. 2022 Oct 5. doi: 10.1111/jvh.13756.
    PubMed     Abstract available
    
    
    
70. MENDIZABAL M, Thompson M, Gonzalez-Ballerga E, Anders M, et al
    Implementation of a re-linkage to care strategy in patients with chronic hepatitis C who were lost to follow-up in Latin America.
    J Viral Hepat. 2022 Oct 5. doi: 10.1111/jvh.13758.
    PubMed     Abstract available
    
    
    
71. BRYCE K, Smith C, Rodger A, Macdonald D, et al
    Falling treatment uptake in the hepatitis C care cascade is a growing threat to achieving elimination.
    J Viral Hepat. 2022 Oct 5. doi: 10.1111/jvh.13757.
    PubMed     Abstract available
    
    
    September 2022
72. QIU LX, Huang Y, Quan JL, Bi ZF, et al
    The prognosis of hepatitis E infection in patients with chronic liver disease: a meta-analysis.
    J Viral Hepat. 2022 Sep 30. doi: 10.1111/jvh.13754.
    PubMed     Abstract available
    
    
    
73. CAREY I, Christiana M, Marie-Ange M, Teresa B, et al
    Universal versus targeted screening for HCV infection in pregnancy in a diverse, multi-ethnic population: universal screening is more comprehensive.
    J Viral Hepat. 2022 Sep 22. doi: 10.1111/jvh.13752.
    PubMed     Abstract available
    
    
    
74. CHOU C, Veracruz N, Chitnis AS, Wong RJ, et al
    Risk of Drug Induced Liver Injury in Chronic Hepatitis B and Tuberculosis Co-infection: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2022 Sep 22. doi: 10.1111/jvh.13751.
    PubMed     Abstract available
    
    
    
75. MCDANIEL K, Utz AE, Akbashev MY, Fuller K, et al
    Safe co-administration of direct-acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: an international multicenter retrospective cohort study.
    J Viral Hepat. 2022 Sep 14. doi: 10.1111/jvh.13750.
    PubMed     Abstract available
    
    
    
76. DONG C, Song Z, Sun C, Wang K, et al
    HBsAg Seroconversion in De Novo Hepatitis B Virus Infected Pediatric Liver Transplant Recipients with Antiviral Therapy.
    J Viral Hepat. 2022 Sep 12. doi: 10.1111/jvh.13749.
    PubMed     Abstract available
    
    
    
77. QI T, Zhu C, Wang J, Li B, et al
    MELD Score <18 Rule out 28-day ACLF Development among Inpatients with Hepatitis B Related Previous Compensated Liver Disease.
    J Viral Hepat. 2022 Sep 8. doi: 10.1111/jvh.13747.
    PubMed     Abstract available
    
    
    
78. YANG AH, Yardeni D, Hercun J, Kleiner DE, et al
    Shear Wave Elastography: How well does it perform in Chronic Hepatitis D Virus Infection?
    J Viral Hepat. 2022 Sep 5. doi: 10.1111/jvh.13745.
    PubMed     Abstract available
    
    
    
79. HARTL L, Jachs M, Bauer D, Simbrunner B, et al
    An HCV hotline facilitates Hepatitis C elimination during the COVID-19 pandemic.
    J Viral Hepat. 2022 Sep 5. doi: 10.1111/jvh.13746.
    PubMed     Abstract available
    
    
    
80. REYNOLDS L, Franco R, Prado M, Rodgers JB, et al
    Hepatitis C Active Viremia Over Time in an ED-based Testing Program: Impact, Disparities,.
    J Viral Hepat. 2022 Sep 5. doi: 10.1111/jvh.13744.
    PubMed     Abstract available
    
    
    
81. JHA AK
    Hepatitis of unknown origin in children: Updated evidence and concise review.
    J Viral Hepat. 2022 Sep 5. doi: 10.1111/jvh.13743.
    PubMed     Abstract available
    
    
    
82. LIEM KS, Chi H, Fung S, Wong DK, et al
    Early virologic relapse predicts ALT flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B.
    J Viral Hepat. 2022 Sep 1. doi: 10.1111/jvh.13742.
    PubMed     Abstract available
    
    
    August 2022
83. SAMALA N, Wang RY, Auh S, Kara Balla A, et al
    Hepatitis E Prevalence and Infection in Solid-Organ Transplant Recipients in the United States.
    J Viral Hepat. 2022 Aug 29. doi: 10.1111/jvh.13739.
    PubMed     Abstract available
    
    
    
84. YOUNOSSI ZM, Yu ML, El-Kassas M, Esmat G, et al
    Severe Impairment of Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Seen in Real-World Practices Across the World: Data from the Global Liver Registry.
    J Viral Hepat. 2022 Aug 29. doi: 10.1111/jvh.13741.
    PubMed     Abstract available
    
    
    
85. YAMADA R, Morikawa K, Hotta K, Iwami D, et al
    Incidence of post-transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection.
    J Viral Hepat. 2022 Aug 29. doi: 10.1111/jvh.13740.
    PubMed     Abstract available
    
    
    
86. MARTIN M, Roth PJ, Niu J, Pericot-Valverde I, et al
    Changes in Alcohol Use during Hepatitis C Treatment in Persons Who Inject Drugs.
    J Viral Hepat. 2022 Aug 23. doi: 10.1111/jvh.13737.
    PubMed     Abstract available
    
    
    
87. BARRANCO MA, Rosenberg ES, Flanigan C, Shufelt S, et al
    A cross-sectional study of Hepatitis C prevalence and correlates among persons who inject drugs in rural and non-rural communities.
    J Viral Hepat. 2022 Aug 4. doi: 10.1111/jvh.13735.
    PubMed     Abstract available
    
    
    
88. JIN D, Brener L, Treloar C
    Trust in healthcare providers among Chinese immigrants living with hepatitis B virus in Australia: A qualitative study.
    J Viral Hepat. 2022 Aug 3. doi: 10.1111/jvh.13736.
    PubMed     Abstract available
    
    
    
89. XU L, Li X, Lu L, Liu X, et al
    HBV pgRNA profiles in Chinese HIV/HBV coinfected patients under pre- and posttreatment: a multicentre observational cohort study.
    J Viral Hepat. 2022;29:616-626.
    PubMed     Abstract available
    
    
    July 2022
90. DENG X, Guo X, Gu H, Wang D, et al
    Anti-HBc-nonreactive occult hepatitis B infections with HBV genotypes B and C in vaccinated immunocompetent adults.
    J Viral Hepat. 2022 Jul 25. doi: 10.1111/jvh.13733.
    PubMed     Abstract available
    
    
    
91. GAO N, Yu H, Zhang J, Mo Z, et al
    Role of Hepatitis B Surface Antibody in Seroreversion of Hepatitis B Surface Antigen in Patients Achieving Hepatitis B Surface Antigen Loss with Pegylated Interferon-Based Therapy.
    J Viral Hepat. 2022 Jul 24. doi: 10.1111/jvh.13734.
    PubMed     Abstract available
    
    
    
92. MUTIMER D, Elsharkawy A, Hathorn E, Arunkumar S, et al
    Hepatitis B e antigen and e antibody in a multi-ethnic cohort of adult chronic hepatitis B virus patients followed at a single liver unit for a period of 20 years.
    J Viral Hepat. 2022 Jul 6. doi: 10.1111/jvh.13731.
    PubMed     Abstract available
    
    
    
93. WANG H, Tong J, Xu X, Chen J, et al
    Reversibility of acute-on-chronic liver failure syndrome in hepatitis B virus-infected patients with and without prior decompensation.
    J Viral Hepat. 2022 Jul 6. doi: 10.1111/jvh.13732.
    PubMed     Abstract available
    
    
    
94. KUMADA T, Toyoda H, Yasuda S, Ito T, et al
    Original article Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus.
    J Viral Hepat. 2022 Jul 5. doi: 10.1111/jvh.13728.
    PubMed     Abstract available
    
    
    
95. PAPATHEODORIDI M, Papachristou E, Moschidis Z, Hadziyannis E, et al
    Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy.
    J Viral Hepat. 2022 Jul 5. doi: 10.1111/jvh.13729.
    PubMed     Abstract available
    
    
    
96. FORD JS, Hollywood E, Steuble B, Meng Z, et al
    Risk Factors for Hepatitis C Virus Infection at a Large Urban Emergency Department.
    J Viral Hepat. 2022 Jul 5. doi: 10.1111/jvh.13730.
    PubMed     Abstract available
    
    
    June 2022
97. FACTOR SH, Fierer DS
    Can Treatment, Without Prevention, Eliminate Hepatitis C Among Men Who Have Sex With Men?
    J Viral Hepat. 2022 Jun 24. doi: 10.1111/jvh.13726.
    PubMed    
    
    
    
98. SHATA MTM, Hetta HF, Sharma Y, Sherman KE, et al
    Viral Hepatitis in Pregnancy.
    J Viral Hepat. 2022 Jun 24. doi: 10.1111/jvh.13725.
    PubMed     Abstract available
    
    
    
99. TAYE BW, Valery PC, Clark PJ
    Targeted antiviral treatment of hepatitis B virus in culturally and linguistically diverse populations to achieve elimination targets in Australia.
    J Viral Hepat. 2022 Jun 24. doi: 10.1111/jvh.13727.
    PubMed     Abstract available
    
    
    
100. XU JH, Fan YN, Yu YY, Si CW, et al
     240-week Entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C.
     J Viral Hepat. 2022 Jun 23. doi: 10.1111/jvh.13724.
     PubMed     Abstract available
     
     
     
101. TRAEGER MW, van Santen DK, Sacks-Davis R, Asselin J, et al
     Impact of COVID-19 lockdown restrictions on hepatitis C testing in Australian primary care services providing care for people who inject drugs.
     J Viral Hepat. 2022 Jun 20. doi: 10.1111/jvh.13723.
     PubMed     Abstract available
     
     
     
102. YAO N, Wang J, Wu Y, Zhu Y, et al
     Frequent alanine aminotransferase flares and promising antiviral therapy efficacy during the preschool age: an opportunity to achieve HBsAg loss in children with mother-to-child transmitted hepatitis B.
     J Viral Hepat. 2022 Jun 20. doi: 10.1111/jvh.13720.
     PubMed     Abstract available
     
     
     
103. LIM J, Lee JB, An J, Song GW, et al
     Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000-Korean outcome study.
     J Viral Hepat. 2022 Jun 19. doi: 10.1111/jvh.13721.
     PubMed     Abstract available
     
     
     
104. CHU JH, Huang Y, Xie DY, Deng H, et al
     Real-world study on HBsAg loss of combination therapy in HBeAg-negative chronic hepatitis B patients.
     J Viral Hepat. 2022 Jun 19. doi: 10.1111/jvh.13722.
     PubMed     Abstract available
     
     
     
105. RIOS-HINCAPIE CY, Murad-Rivera R, Tohme RA, Ropero AM, et al
     Progress towards the elimination of hepatitis B in children in Colombia: a novel two-phase study approach.
     J Viral Hepat. 2022 Jun 16. doi: 10.1111/jvh.13719.
     PubMed     Abstract available
     
     
     
106. SHIHA G, Soliman R, Mikhail NNH, Carrat F, et al
     International Multicenter Validation of GES score for HCC risk stratification in chronic hepatitis C patients.
     J Viral Hepat. 2022 Jun 3. doi: 10.1111/jvh.13717.
     PubMed     Abstract available
     
     
     
107. EVON DM, Dong M, Reeve BB, Peter J, et al
     Sustainable and Equivalent Improvements in Symptoms and Functional Well-Being Following Viral Cure from Ledipasvir/Sofosbuvir versus Elbasvir/Grazoprevir for Chronic Hepatitis C Infection: Findings from the randomized PRIORITIZE trial.
     J Viral Hepat. 2022 Jun 3. doi: 10.1111/jvh.13716.
     PubMed     Abstract available
     
     
     
108. HSU WF, Lai HC, Chuang PH, Su WP, et al
     Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liver-related complications in patients with chronic hepatitis C receiving direct-acting antiviral agents.
     J Viral Hepat. 2022 Jun 3. doi: 10.1111/jvh.13715.
     PubMed     Abstract available
     
     
     
109. ROBINS A, Dolman G, Williams S, Gelson W, et al
     Hepatitis E Case Series. A UK Experience.
     J Viral Hepat. 2022 Jun 2. doi: 10.1111/jvh.13714.
     PubMed     Abstract available
     
     
     May 2022
110. MARKAKIS GE, Papatheodoridis GV, Cholongitas E
     Epidemiology and treatment of hepatitis E in the liver transplantation setting: A literature review.
     J Viral Hepat. 2022 May 29. doi: 10.1111/jvh.13709.
     PubMed     Abstract available
     
     
     
111. ASKAR S, Jelley R, McQue K, Allsop C, et al
     Determining the frequency and characteristics of Hepatitis C reinfections in North East England.
     J Viral Hepat. 2022 May 29. doi: 10.1111/jvh.13707.
     PubMed     Abstract available
     
     
     
112. RAMOS-RINCON JM, Pinargote-Celorio H, de Mendoza C, Ramos-Belinchon C, et al
     Hepatitis C Hospitalizations in Spain and Impact of New Curative Antiviral Therapies.
     J Viral Hepat. 2022 May 29. doi: 10.1111/jvh.13708.
     PubMed     Abstract available
     
     
     
113. BOLLERUP S, Hallager S, Engsig F, Mocroft A, et al
     Mortality and cause of death in persons with chronic hepatitis B virus infection versus healthy persons from the general population in Denmark.
     J Viral Hepat. 2022 May 27. doi: 10.1111/jvh.13713.
     PubMed     Abstract available
     
     
     
114. CHEN L, Zhu L, Lu X, Ming X, et al
     TRPM2 regulates autophagy to participate in hepatitis B virus replication.
     J Viral Hepat. 2022 May 27. doi: 10.1111/jvh.13710.
     PubMed     Abstract available
     
     
     
115. EYMIEUX S, Hourioux C, Marlet J, Moreau A, et al
     A morphometric analysis of hepatitis B subviral particles shows no correlation of filament proportion and length with clinical stage and genotype.
     J Viral Hepat. 2022 May 27. doi: 10.1111/jvh.13712.
     PubMed     Abstract available
     
     
     
116. MARLEY G, Seto WK, Yan W, Chan P, et al
     What facilitates hepatitis B and hepatitis C testing and the role of stigma among primary care patients in China?
     J Viral Hepat. 2022 May 27. doi: 10.1111/jvh.13711.
     PubMed     Abstract available
     
     
     
117. PRINSENBERG T, Schinkel J, Zantkuijl P, Davidovich U, et al
     Internet-guided HCV-RNA testing: A promising tool to achieve hepatitis C micro-elimination among men who have sex with men.
     J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13706.
     PubMed     Abstract available
     
     
     
118. CARSON JM, Hajarizadeh B, Hanson J, O'Beirne J, et al
     Retreatment for hepatitis C virus direct acting antiviral therapy virological failure in primary and tertiary settings: the REACH-C cohort.
     J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13705.
     PubMed     Abstract available
     
     
     
119. ZHENG K, Xia T, Liu N, Xia X, et al
     MicroRNA-206 inhibits HCV proliferation through depressing ACC1 lipid synthesis signaling pathway.
     J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13703.
     PubMed     Abstract available
     
     
     
120. MASLAC O, Wagner J, Sozzi V, Mason H, et al
     Secreted Hepatitis B virus splice variants differ by HBV genotype and across phases of chronic hepatitis B infection.
     J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13702.
     PubMed     Abstract available
     
     
     
121. BEER L, Inglis S, Malaguti A, Byrne C, et al
     Randomised Clinical Trial: Direct-acting antivirals as treatment for hepatitis C in people who inject drugs: delivered in needle and syringe programs via directly observed therapy versus fortnightly collection.
     J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13701.
     PubMed     Abstract available
     
     
     
122. ZHOU G, Chen C, Han G, Jiang H, et al
     Relationship between different hepatitis B virus infection status and gestational diabetes mellitus prevalence among pregnant women with chronic HBV infection: a retrospective study.
     J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13700.
     PubMed     Abstract available
     
     
     
123. XU Y, Qi W, Wang X, Zhang Y, et al
     Signal transducer and activator of transcription 3 cooperates with androgen receptor/cell cycle-related kinase signalling pathway in the progression of hepatitis B virus infection and gender differences.
     J Viral Hepat. 2022 May 14. doi: 10.1111/jvh.13699.
     PubMed     Abstract available
     
     
     
124. VARGAS-ACCARINO E, Martinez-Camprecios J, Dominguez-Hernandez R, Rando-Segura A, et al
     Cost-effectiveness analysis of an active search to retrieve HCV patients lost to follow-up (RELINK-C strategy) and the impact of COVID-19.
     J Viral Hepat. 2022 May 12. doi: 10.1111/jvh.13686.
     PubMed     Abstract available
     
     
     
125. MASHIBA T, Joko K, Kurosaki M, Ochi H, et al
     Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Live
     J Viral Hepat. 2022 May 12. doi: 10.1111/jvh.13684.
     PubMed     Abstract available
     
     
     
126. JONES AT, Briones C, Tran T, Moreno-Walton L, et al
     Closing the hepatitis C treatment gap: United States strategies to improve retention in care.
     J Viral Hepat. 2022 May 12. doi: 10.1111/jvh.13685.
     PubMed     Abstract available
     
     
     
127. HEALY K, Freij U, Ellerstad M, Aulin LBS, et al
     Evaluating the prevalence of Hepatitis E virus infection in a large cohort of European blood donors, 2015-2018.
     J Viral Hepat. 2022 May 2. doi: 10.1111/jvh.13682.
     PubMed     Abstract available
     
     
     
128. KUWANO A, Yada M, Nagasawa S, Tanaka K, et al
     Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib.
     J Viral Hepat. 2022 May 2. doi: 10.1111/jvh.13681.
     PubMed     Abstract available
     
     
     March 2022
129. LEE J, Ahn SB, Yim SY, An J, et al
     Efficacy and Safety of Direct-Acting Antiviral Therapy for Hepatitis C Virus in Elderly Patients (>/= 65 years old): A Systematic Review and Meta-Analysis.
     J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13679.
     PubMed     Abstract available
     
     
     
130. TERGAST TL, Blach S, Tacke F, Berg T, et al
     Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany.
     J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13680.
     PubMed     Abstract available
     
     
     
131. HASSAN A, Agustin HGS, Burke L, Kofron R, et al
     Low Incidence and Prevalence of Hepatitis C in Two Cohorts of HIV Pre-Exposure Prophylaxis Adherence Interventions in Men Who Have Sex with Men in Southern California.
     J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13678.
     PubMed     Abstract available
     
     
     
132. WARD E, Carlisle N, Williams E, Heath SL, et al
     Prevalence of Hepatitis C in Sexual Assault Survivors Presenting to a SANE Clinic: A Descriptive Analysis.
     J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13675.
     PubMed     Abstract available
     
     
     
133. LIU R, Li M, Lu Y, Zhang L, et al
     Hepatitis B core-related antigen serum levels are associated with significant liver fibrosis in treatment-naive chronic HBV infection patients.
     J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13674.
     PubMed     Abstract available
     
     
     
134. NEBBIA G, Ruf M, Hunter L, Balasegaram S, et al
     The VirA+EmiC project - Evaluating real-world effectiveness and sustainability of integrated routine opportunistic hepatitis B and C testing in a large urban emergency department.
     J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13676.
     PubMed     Abstract available
     
     
     
135. KRARUP HB, Rex KF, Andersen S
     Mortality in Greenlanders with chronic hepatitis B virus infection.
     J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13673.
     PubMed     Abstract available
     
     
     
136. OZGA JE, Syvertsen JL, Pollini RA
     Hepatitis C Antibody Prevalence, Correlates, and Barriers to Care among People Who Inject Drugs in Central California.
     J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13677.
     PubMed     Abstract available
     
     
     
137. KRINGS A, Schmidt D, Meixenberger K, Bannert N, et al
     Decreasing prevalence and stagnating incidence of Hepatitis C-coinfection among a cohort of HIV-1-positive patients, with a majority of men who have sex with men, in Germany, 1996-2019.
     J Viral Hepat. 2022 Mar 18. doi: 10.1111/jvh.13670.
     PubMed     Abstract available
     
     
     
138. MA Z, Qin Y, Jia Y, Yiran X, et al
     Thyroid dysfunction incidence and risk factors in Chinese chronic hepatitis B patients treated with pegylated interferon alpha: a long-term follow-up study.
     J Viral Hepat. 2022 Mar 16. doi: 10.1111/jvh.13667.
     PubMed     Abstract available
     
     
     
139. MORGAN JR, Marsh E, Savinkina A, Shilton S, et al
     Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral based treatment regimens: evidence from a global dataset.
     J Viral Hepat. 2022 Mar 12. doi: 10.1111/jvh.13672.
     PubMed     Abstract available
     
     
     
140. VERACRUZ N, Gish RG, Cheung R, Chitnis AS, et al
     Global incidence and mortality of hepatitis B and hepatitis C acute infections, cirrhosis and hepatocellular carcinoma from 2010 to 2019.
     J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13663.
     PubMed     Abstract available
     
     
     
141. HOWELL J, Traeger MW, Williams B, Layton C, et al
     The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study.
     J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13664.
     PubMed     Abstract available
     
     
     
142. CHROMY D, Bauer DJM, Simbrunner B, Jachs M, et al
     'Viennese epidemic' of acute HCV in the era of direct-acting antivirals.
     J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13665.
     PubMed     Abstract available
     
     
     
143. EL EKIABY M, Tanaka J, van Drimmelen H, Allain JP, et al
     Infectivity of hepatitis B virus (HBV) surface antigen (HBsAg) positive plasma with undetectable HBV-DNA: Can HBsAg screening be discontinued in Egyptian blood donors?
     J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13666.
     PubMed     Abstract available
     
     
     
144. AKIYAMA MJ, Riback L, Nyakowa M, Musyoki H, et al
     Hepatitis C Treatment Outcomes Among People Who Inject Drugs Accessing Harm Reduction Settings in Kenya.
     J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13662.
     PubMed     Abstract available
     
     
     
145. ZENG X, Ayibaota B, Tuerhanbayi B, Zheng M, et al
     The altered HLA-DQ expression in peripheral blood T cells of chronic hepatitis B patients characterizes the function of T cells.
     J Viral Hepat. 2022 Mar 10. doi: 10.1111/jvh.13669.
     PubMed     Abstract available
     
     
     
146. WANG Y, Liao H, Deng Z, Liu Y, et al
     Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues.
     J Viral Hepat. 2022 Mar 10. doi: 10.1111/jvh.13671.
     PubMed     Abstract available
     
     
     
147. KAUR H, Dhiman RK, Kulkarni AV, Premkumar M, et al
     Improvement of Chronic HCV infection related Depression, Anxiety, and Neurocognitive performance in persons achieving SVR-12: a Real-world Cohort Study.
     J Viral Hepat. 2022 Mar 10. doi: 10.1111/jvh.13668.
     PubMed     Abstract available
     
     
     
148. NEPHEW LD, Wang Y, Mohamed K, Nichols D, et al
     Removal of Medicaid Restrictions were Associated with Increased Hepatitis-C Virus Treatment Rates, But Disparities Persist.
     J Viral Hepat. 2022 Mar 7. doi: 10.1111/jvh.13661.
     PubMed     Abstract available
     
     
     
149. JI DZ, Pang XY, Shen DT, Liu SN, et al
     Global prevalence of occult Hepatitis B: a systematic review and meta-analysis.
     J Viral Hepat. 2022 Mar 7. doi: 10.1111/jvh.13660.
     PubMed     Abstract available
     
     
     
150. TAN Q, Chen J, Gao G, Yizhang, et al
     Adenovirus vector encoding TPPII ignites HBV-specific CTL response by activating autophagy in CD8+ T cell.
     J Viral Hepat. 2022;29:178-188.
     PubMed     Abstract available
     
     
     February 2022
151. HOSSEINI-HOOSHYAR S, Alavi M, Martinello M, Valerio H, et al
     Evaluation of the hepatitis C cascade of care among people living with HIV in New South Wales, Australia: A data linkage study.
     J Viral Hepat. 2022 Feb 17. doi: 10.1111/jvh.13658.
     PubMed     Abstract available
     
     
     
152. WU G, Zhou A, Kwon S
     Integrating Hepatitis C Virus Screening of Baby Boomers at a Community Hospital Emergency Department.
     J Viral Hepat. 2022 Feb 13. doi: 10.1111/jvh.13654.
     PubMed     Abstract available
     
     
     
153. CHON YE, Park SY, Kim SU, Hong HP, et al
     Long-term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study.
     J Viral Hepat. 2022 Feb 13. doi: 10.1111/jvh.13656.
     PubMed     Abstract available
     
     
     
154. FENG R, Liu Y, Zhu XL, Zhai WY, et al
     Recombinant human thrombopoietin increases platelet count in severe thrombocytopenic patients with hepatitis B related cirrhosis: multi-center real-world observational study.
     J Viral Hepat. 2022 Feb 13. doi: 10.1111/jvh.13655.
     PubMed     Abstract available
     
     
     
155. YARDENI D, Heller T, Koh C
     Chronic hepatitis D - What is changing?
     J Viral Hepat. 2022 Feb 4. doi: 10.1111/jvh.13651.
     PubMed     Abstract available
     
     
     
156. WU A, Liu Y
     Use of HBV DNA and liver stiffness in predicting clinical events in patients with chronic hepatitis B.
     J Viral Hepat. 2022 Feb 4. doi: 10.1111/jvh.13653.
     PubMed    
     
     
     
157. KHERA T, Madsen LW, Du Y, Lillevang ST, et al
     Soluble inflammatory mediators identify HCV patients who may be cured with four weeks of antiviral treatment.
     J Viral Hepat. 2022 Feb 4. doi: 10.1111/jvh.13652.
     PubMed     Abstract available
     
     
     January 2022
158. HUA R, Kong F, Wen X, Xiong Q, et al
     Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection - an open-label, phase 2 study.
     J Viral Hepat. 2022 Jan 26. doi: 10.1111/jvh.13650.
     PubMed     Abstract available
     
     
     
159. WU S, Yuan H, Fan H, Xu Y, et al
     Evolutionary characteristics and immune mutation of hepatitis C virus genotype 1b among intravenous drug users in mainland, China.
     J Viral Hepat. 2022 Jan 25. doi: 10.1111/jvh.13647.
     PubMed     Abstract available
     
     
     
160. LU Z, Zhou Y, Yan R, Deng X, et al
     Post vaccination serologic testing of infants born to hepatitis B surface antigen positive mothers is more Cost-effective in Zhejiang Province,China: A Markov chain analysis.
     J Viral Hepat. 2022 Jan 25. doi: 10.1111/jvh.13649.
     PubMed     Abstract available
     
     
     
161. CHOI WM, Lim YS
     Use of HBV DNA and liver stiffness in predicting clinical events in patients with chronic hepatitis B.
     J Viral Hepat. 2022 Jan 25. doi: 10.1111/jvh.13648.
     PubMed    
     
     
     
162. STOCKDALE AJ, Kreuels B, Shawa IT, Meiring JE, et al
     A clinical and molecular epidemiological survey of hepatitis C in Blantyre, Malawi suggests an historic mechanism of transmission.
     J Viral Hepat. 2022 Jan 25. doi: 10.1111/jvh.13646.
     PubMed     Abstract available
     
     
     
163. WASUWANICH P, Striley CW, Kamili S, Teshale EH, et al
     Hepatitis D-Associated Hospitalizations in the United States: 2010-2018.
     J Viral Hepat. 2022 Jan 25. doi: 10.1111/jvh.13645.
     PubMed     Abstract available
     
     
     
164. ZHANG Y, Yang M, Huang X, Yang H, et al
     Comments on: The role of caesarean section and nonbreastfeeding in preventing mother-to-child transmission of hepatitis B virus in HBsAg-and HBeAg-positive mothers: results from a prospective cohort study and a meta-analysis.
     J Viral Hepat. 2022 Jan 8. doi: 10.1111/jvh.13641.
     PubMed    
     
     
     
165. PAN YC, Jia ZF, Wu YH, Lv HY, et al
     Response to comments on: The role of caesarean section and nonbreastfeeding in preventing mother-to-child transmission of hepatitis B virus in HBsAg-and HBeAg-positive mothers: results from a prospective cohort study and a meta-analysis.
     J Viral Hepat. 2022 Jan 6. doi: 10.1111/jvh.13642.
     PubMed    
     
     
     
166. IKENAGA H, Uchida-Kobayashi S, Tamori A, Odagiri N, et al
     Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment.
     J Viral Hepat. 2022;29:52-59.
     PubMed     Abstract available
     
     
     
167. ELZEFZAFY W, Soliman R, Saleh L, Mahmoud S, et al
     Seroprevalence and epidemiological characteristics of HDV infection among HBV patients in the Nile Delta, Egypt.
     J Viral Hepat. 2022;29:87-90.
     PubMed     Abstract available
     
     
     December 2021
168. ZHOU Y, Li J, Gordon SC, Trudeau S, et al
     Laboratory monitoring and antiviral treatment for chronic hepatitis B among routine care patients in the United States.
     J Viral Hepat. 2021 Dec 14. doi: 10.1111/jvh.13639.
     PubMed     Abstract available
     
     
     
169. WANG XD, Pan CW, Zhou GY, Gao F, et al
     Effect of liver steatosis on liver stiffness measurement in chronic hepatitis B patients with normal serum alanine aminotransferase levels: A multicentre cohort study.
     J Viral Hepat. 2021 Dec 13. doi: 10.1111/jvh.13640.
     PubMed     Abstract available
     
     
     
170. CHOI HSJ, Sonneveld MJ, Farag MS, Brouwer WP, et al
     Effects of on-treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection.
     J Viral Hepat. 2021;28:1729-1737.
     PubMed     Abstract available
     
     
     
171. DJORDJEVIC F, Ryan K, Gunn J, Brener L, et al
     Health service utilization and experiences of stigma amongst people who inject drugs in Melbourne, Australia.
     J Viral Hepat. 2021;28:1738-1743.
     PubMed     Abstract available
     
     
     November 2021
172. MANDEL E, Peci A, Cronin K, Capraru CI, et al
     The Impact of the First, Second, and Third Waves of COVID-19 on Hepatitis B and C Testing in Ontario, Canada.
     J Viral Hepat. 2021 Nov 25. doi: 10.1111/jvh.13637.
     PubMed     Abstract available
     
     
     
173. GIADANS CG, Rios DA, Ameigeiras B, Haddad L, et al
     Intrahepatic immune infiltrate in chronic hepatitis B and chronic hepatitis C: Similar but not the same.
     J Viral Hepat. 2021 Nov 25. doi: 10.1111/jvh.13635.
     PubMed     Abstract available
     
     
     
174. LEMOINE M, Ndow G, Shimakawa Y
     Improving disease knowledge is critical to eliminate hepatitis B.
     J Viral Hepat. 2021 Nov 22. doi: 10.1111/jvh.13633.
     PubMed     Abstract available
     
     
     
175. FORNS X, Colom J, Garcia-Retortillo M, Quer JC, et al
     Point-of-care hepatitis C testing and treatment strategy for people attending harm reduction and addiction centres for hepatitis C elimination.
     J Viral Hepat. 2021 Nov 22. doi: 10.1111/jvh.13634.
     PubMed     Abstract available
     
     
     
176. MOHAMED EI, El-Ghnam SM, Bayoumi AM, Abdel-Mageed SM, et al
     Electronic Nose versus Quadrupole Mass Spectrometry for Identifying Viral Hepatitis C Patients.
     J Viral Hepat. 2021 Nov 12. doi: 10.1111/jvh.13630.
     PubMed     Abstract available
     
     
     
177. CHIDWICK K, Myton R, Rodgers A, Jun M, et al
     A cluster randomized controlled trial of a MedicineInsight Educational Quality Improvement Programme to improve the diagnosis and treatment of chronic hepatitis C in general practice (the EQUIP-HEPC trial).
     J Viral Hepat. 2021 Nov 11. doi: 10.1111/jvh.13629.
     PubMed     Abstract available
     
     
     
178. JO AJ, Choi WM, Kim HJ, Choi SH, et al
     A risk scoring system to predict clinical events in chronic hepatitis B virus infection: A nationwide cohort study.
     J Viral Hepat. 2021 Nov 11. doi: 10.1111/jvh.13631.
     PubMed     Abstract available
     
     
     
179. CHANG HL, Wen WH, Lee CN, Chiu YE, et al
     Kinetics of Hepatitis B Surface Antigen in Pregnant Women with and without Tenofovir Disoproxil Fumarate.
     J Viral Hepat. 2021 Nov 1. doi: 10.1111/jvh.13628.
     PubMed     Abstract available
     
     
     
180. GANE E, de Ledinghen V, Dylla DE, Rizzardini G, et al
     Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.
     J Viral Hepat. 2021;28:1635-1642.
     PubMed     Abstract available
     
     
     October 2021
181. JUGNARAIN DV, Halford R, Smith S, Hickman M, et al
     Role of peer support in a hepatitis C elimination program.
     J Viral Hepat. 2021 Oct 18. doi: 10.1111/jvh.13626.
     PubMed     Abstract available
     
     
     
182. KUWANO A, Yada M, Nagasawa S, Tanaka K, et al
     Serum alpha-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
     J Viral Hepat. 2021 Oct 18. doi: 10.1111/jvh.13625.
     PubMed     Abstract available
     
     
     
183. RAMIREZ MENA A, Tine JM, Fortes L, Ndiaye O, et al
     Hepatitis B screening practices and viral control among persons living with HIV in urban Senegal.
     J Viral Hepat. 2021 Oct 5. doi: 10.1111/jvh.13615.
     PubMed     Abstract available
     
     
     
184. ZHOU Y, Lu Z, He H, Yan R, et al
     Influencing factors and necessity of post-vaccination serologic testing follow-up for HBsAg-positive mothers and their infants: A 5-year prospective study in Zhejiang Province, China (2016-2020).
     J Viral Hepat. 2021;28:1413-1421.
     PubMed     Abstract available
     
     
     September 2021
185. NISHIGUCHI J, McNamara A, Surlyn CS, Eagen KV, et al
     Efficacy of an eConsult Service to Cure Hepatitis C in Primary Care.
     J Viral Hepat. 2021 Sep 29. doi: 10.1111/jvh.13616.
     PubMed     Abstract available
     
     
     
186. COPPOLA C, Masarone M, Bartoli M, Staiano L, et al
     Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: a cohort study.
     J Viral Hepat. 2021 Sep 29. doi: 10.1111/jvh.13623.
     PubMed     Abstract available
     
     
     
187. STROFFOLINI T, Morisco F, Ferrigno L, Pontillo G, et al
     Acute Delta Hepatitis in Italy spanning three decades (1991-2019): evidence for the effectiveness of the hepatitis B vaccination campaign.
     J Viral Hepat. 2021 Sep 29. doi: 10.1111/jvh.13620.
     PubMed     Abstract available
     
     
     
188. HARNEY BL, Brereton R, Whitton B, Pietrzak D, et al
     Letter in response: Psychiatrists can treat hepatitis C.
     J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13619.
     PubMed     Abstract available
     
     
     
189. RODER C, Nguyen P, Harvey C, Wardrop M, et al
     Psychiatrists can treat hepatitis C.
     J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13622.
     PubMed     Abstract available
     
     
     
190. ROSATO V, Ascione A, Nevola R, Fracanzani AL, et al
     Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: a multicenter prospective study.
     J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13617.
     PubMed     Abstract available
     
     
     
191. SOHN W, Chang Y, Cho YK, Hong YS, et al
     Liver fibrosis scores and risk of liver-related mortality in young adults with chronic hepatitis B: A cohort study.
     J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13618.
     PubMed     Abstract available
     
     
     
192. CAVEN M, Baiano CX, Robinson EM, Stephens B, et al
     Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland.
     J Viral Hepat. 2021 Sep 15. doi: 10.1111/jvh.13614.
     PubMed     Abstract available
     
     
     
193. KOUTSIANAS C, Hadziyannis E, Thomas K, Deutsch M, et al
     Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents.
     J Viral Hepat. 2021 Sep 8. doi: 10.1111/jvh.13610.
     PubMed     Abstract available
     
     
     
194. MARCELLIN F, Di Beo V, Esterle L, Abgrall S, et al
     Post-HCV cure self-reported changes in physical activity, eating behaviors, and fatigue in people living with HIV (ANRS CO13 HEPAVIH).
     J Viral Hepat. 2021 Sep 2. doi: 10.1111/jvh.13605.
     PubMed     Abstract available
     
     
     
195. DOUMBIA M, Sevede D, Kouakou V, Kouakou C, et al
     Viral and bacterial factors of mother-to-child transmission of hepatitis B virus.
     J Viral Hepat. 2021 Sep 1. doi: 10.1111/jvh.13607.
     PubMed     Abstract available
     
     
     
196. HAMDIUI N, van Steenbergen J, Rocha LEC, Meiberg A, et al
     Hepatitis B screening among immigrants: how to successfully reach the Moroccan community.
     J Viral Hepat. 2021 Sep 1. doi: 10.1111/jvh.13604.
     PubMed     Abstract available
     
     
     
197. CHEUNG KW, Seto MTY, Tsui PM, So PL, et al
     Knowledge, perception and expectation of management of hepatitis B infection among pregnant hepatitis B carriers in Hong Kong.
     J Viral Hepat. 2021 Sep 1. doi: 10.1111/jvh.13609.
     PubMed     Abstract available
     
     
     
198. ERKEN R, Andre P, Roy E, Kootstra N, et al
     Farnesoid X receptor agonist for the treatment of chronic hepatitis B; a safety study.
     J Viral Hepat. 2021 Sep 1. doi: 10.1111/jvh.13608.
     PubMed     Abstract available
     
     
     
199. GARCIA-CEHIC D, Rando A, Rodriguez-Frias F, Gregori J, et al
     Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure.
     J Viral Hepat. 2021;28:1319-1324.
     PubMed     Abstract available
     
     
     August 2021
200. TSAI HJ, Chuang YW, Yang SS, Chang YZ, et al
     Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease.
     J Viral Hepat. 2021 Aug 31. doi: 10.1111/jvh.13603.
     PubMed     Abstract available
     
     
     
201. WANG L, Zhao J, Liu J, Zhen C, et al
     Long-term benefits of interferon-alpha therapy in children with HBeAg-positive immune-active chronic hepatitis B.
     J Viral Hepat. 2021 Aug 26. doi: 10.1111/jvh.13598.
     PubMed     Abstract available
     
     
     
202. LEE HW, Cho YY, Lee H, Lee JS, et al
     Effect of tenofovir alafenamide versus tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B.
     J Viral Hepat. 2021 Aug 26. doi: 10.1111/jvh.13601.
     PubMed     Abstract available
     
     
     
203. CHEN Y, Zhao YL, Hao ZY, Zhang XJ, et al
     Long-term persistence of anti-HAV antibody conferred by a single dose of live-attenuated hepatitis A vaccine: results from 17-year follow-up.
     J Viral Hepat. 2021 Aug 26. doi: 10.1111/jvh.13602.
     PubMed     Abstract available
     
     
     
204. WONG RJ, Cheung R, Gish RG, Chitnis AS, et al
     Prevalence of Hepatitis E Infection among Adults with Concurrent Chronic Liver Disease.
     J Viral Hepat. 2021 Aug 20. doi: 10.1111/jvh.13597.
     PubMed     Abstract available
     
     
     
205. CHEN B, Huang H, Pan CQ
     The Role of Gut Microbiota in Hepatitis B Disease Progression and Treatment.
     J Viral Hepat. 2021 Aug 20. doi: 10.1111/jvh.13595.
     PubMed     Abstract available
     
     
     
206. PALMER AY, Chan K, Gold J, Layton C, et al
     A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign.
     J Viral Hepat. 2021 Aug 20. doi: 10.1111/jvh.13596.
     PubMed     Abstract available
     
     
     
207. CHANG JW, Lee JS, Lee HW, Kim BK, et al
     No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B.
     J Viral Hepat. 2021 Aug 12. doi: 10.1111/jvh.13594.
     PubMed     Abstract available
     
     
     
208. BALL LE, Agana B, Comte-Walters S, Rockey DC, et al
     Hepatitis C Virus Treatment with Direct Acting Antivirals Induces Rapid Changes in the Hepatic Proteome.
     J Viral Hepat. 2021 Aug 11. doi: 10.1111/jvh.13593.
     PubMed     Abstract available
     
     
     
209. FREELAND C, Racho R, Kamischke M, Moraras K, et al
     Cure everyone and vaccinate the rest: The patient perspective on future hepatitis B treatment.
     J Viral Hepat. 2021 Aug 7. doi: 10.1111/jvh.13592.
     PubMed     Abstract available
     
     
     
210. LEE WM, King WC, Janssen HLA, Ghany MG, et al
     Hepatitis B e Antigen Loss in Adults and Children with Chronic Hepatitis B Living in North America: A Prospective Cohort Study.
     J Viral Hepat. 2021 Aug 6. doi: 10.1111/jvh.13591.
     PubMed     Abstract available
     
     
     
211. PERIERES L, Protopopescu C, Lo G, Marcellin F, et al
     Sibling status, home birth, tattoos and stitches are risk factors for chronic hepatitis B virus infection in Senegalese children: a cross-sectional survey.
     J Viral Hepat. 2021 Aug 6. doi: 10.1111/jvh.13589.
     PubMed     Abstract available
     
     
     
212. DJEBALI-TRABELSI A, Marot A, Andre C, Deltenre P, et al
     Large-scale screening is not useful for identifying individuals with hepatitis B or C virus infection: a prospective Swiss study.
     J Viral Hepat. 2021 Aug 3. doi: 10.1111/jvh.13588.
     PubMed     Abstract available
     
     
     
213. XU C, Bao Y, Zuo J, Li Y, et al
     Maternal chronic hepatitis B virus infection and the risk of preterm birth: a retrospective cohort analysis in Chinese Women.
     J Viral Hepat. 2021 Aug 3. doi: 10.1111/jvh.13585.
     PubMed     Abstract available
     
     
     
214. KNOP V, Hoppe D, Vermehren J, Troetschler S, et al
     Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 year follow-up of a prospective longitudinal study.
     J Viral Hepat. 2021 Aug 3. doi: 10.1111/jvh.13587.
     PubMed     Abstract available
     
     
     
215. HUPPE D, Stoehr A, Buggisch P, Mauss S, et al
     The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R).
     J Viral Hepat. 2021 Aug 2. doi: 10.1111/jvh.13586.
     PubMed     Abstract available
     
     
     July 2021
216. SANTOS-LIMA C, Souza-Marques B, Vieira F, Schinoni MI, et al
     Neuropsychological effects of direct-acting antiviral treatment for HCV subjects: a systematic review.
     J Viral Hepat. 2021 Jul 28. doi: 10.1111/jvh.13584.
     PubMed     Abstract available
     
     
     
217. WANG Y, Zhao Z, Zhang H, Lin Q, et al
     Estimating the transmissibility of hepatitis C: a modelling study in Yichang City, China.
     J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13582.
     PubMed     Abstract available
     
     
     
218. DEL ROSARIO A, Eldredge JD, Doorley S, Mishra SI, et al
     Hepatitis C Virus Care Cascade in Persons Experiencing Homelessness in the United States in the Era of Direct-Acting Antiviral Agents: A Scoping Review.
     J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13583.
     PubMed     Abstract available
     
     
     
219. OHKI T, Satov K, Kondo M, Goto E, et al
     Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
     J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13579.
     PubMed     Abstract available
     
     
     
220. ZHANG S, Chen Z, Wei J, Chi X, et al
     A model based on clinico-biochemical characteristics and deep learning features from MR images for assessing necroinflammatory activity in chronic hepatitis B.
     J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13578.
     PubMed     Abstract available
     
     
     
221. YOUSAFZAI MT, Bajis S, Alavi M, Grebely J, et al
     Treatment cascade of care for chronic hepatitis C virus infection globally: Systematic review and meta-analysis.
     J Viral Hepat. 2021 Jul 26. doi: 10.1111/jvh.13574.
     PubMed     Abstract available
     
     
     
222. HEYWOOD A, Dyda A, Hu W, Saha A, et al
     Seroprevalence of hepatitis B antibodies among international and domestic university students.
     J Viral Hepat. 2021 Jul 26. doi: 10.1111/jvh.13580.
     PubMed     Abstract available
     
     
     
223. KAMAL H, Fornes R, Simin J, Stal P, et al
     Risk of Hepatocellular Carcinoma in Hepatitis B and D Virus Co-Infected Patients: A Systematic Review and Meta-analysis of Longitudinal studies.
     J Viral Hepat. 2021 Jul 22. doi: 10.1111/jvh.13577.
     PubMed     Abstract available
     
     
     
224. BISCHOFF J, Mauss S, Lutz T, Cordes C, et al
     Late presentation of chronic hepatitis C patients in the era of direct acting antivirals - Data from the German Hepatitis C-Registry.
     J Viral Hepat. 2021 Jul 21. doi: 10.1111/jvh.13576.
     PubMed     Abstract available
     
     
     
225. BARDSLEY M, Heinsbroek E, Harris R, Croxford S, et al
     The Impact Of Direct-Acting Antivirals On Hepatitis C Viraemia Among People Who Inject Drugs In England; Real-World Data 2011-2018.
     J Viral Hepat. 2021 Jul 16. doi: 10.1111/jvh.13575.
     PubMed     Abstract available
     
     
     
226. NA JE, Sinn DH, Lee JH, Jang HJ, et al
     Efficacy of entecavir vs tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response.
     J Viral Hepat. 2021 Jul 12. doi: 10.1111/jvh.13572.
     PubMed     Abstract available
     
     
     
227. VARCHETTA S, Mele D, D'Ambrosio R, Perbellini R, et al
     A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C.
     J Viral Hepat. 2021 Jul 6. doi: 10.1111/jvh.13570.
     PubMed     Abstract available
     
     
     
228. LI J, Qu L, Sun X, Liu Y, et al
     Peg-interferon alpha add-on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg positive chronic hepatitis B naive patients.
     J Viral Hepat. 2021 Jul 6. doi: 10.1111/jvh.13571.
     PubMed     Abstract available
     
     
     
229. ERICE A, Varillas-Delgado D, Caballero C
     Prevalence and characteristics of hepatitis C virus infection detected by extended screening of working-age adults in Madrid (Spain).
     J Viral Hepat. 2021 Jul 5. doi: 10.1111/jvh.13564.
     PubMed     Abstract available
     
     
     
230. KAMALAPIRAT T, Ungtrakul T
     Reply to "Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B".
     J Viral Hepat. 2021 Jul 5. doi: 10.1111/jvh.13566.
     PubMed     Abstract available
     
     
     
231. LOU T, Li B, Xiong P, Jin C, et al
     External Validation of Hepatocellular Carcinoma Risk Scores in Patients with Chronic Hepatitis B Virus Infection in China.
     J Viral Hepat. 2021 Jul 4. doi: 10.1111/jvh.13569.
     PubMed     Abstract available
     
     
     
232. FARSIMADAN M, Riahi SM, Muhammad HM, Emamvirdizadeh A, et al
     The Effects of Hepatitis B Virus Infection on Natural and IVF Pregnancy: A Meta-analysis Study.
     J Viral Hepat. 2021 Jul 3. doi: 10.1111/jvh.13565.
     PubMed     Abstract available
     
     
     
233. LIU Y
     Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B.
     J Viral Hepat. 2021 Jul 3. doi: 10.1111/jvh.13568.
     PubMed     Abstract available
     
     
     
234. LIU Y
     Reply to "Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B" - a reply.
     J Viral Hepat. 2021 Jul 3. doi: 10.1111/jvh.13567.
     PubMed     Abstract available
     
     
     
235. MCGUIRE FH, Andre K, Bradsher ML, Harrison D, et al
     Willingness to participate in research among black patients with liver disease: A national cross-sectional study.
     J Viral Hepat. 2021;28:982-993.
     PubMed     Abstract available
     
     
     June 2021
236. GIRALDEZ-GALLEGO A, Rodriguez-Seguel E, Pascasio-Acevedo JM
     Optimal hepatitis B vaccination schedule for cirrhotic patients: a still unanswered question.
     J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13563.
     PubMed     Abstract available
     
     
     
237. KIM HP, Edwards A, Reeve BB, Golin CE, et al
     Symptoms and Functioning Improve after Chronic Hepatitis C Cure as Assessed by the Memorial Symptom Assessment Scale and PROMIS Measures.
     J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13561.
     PubMed     Abstract available
     
     
     
238. KUMADA T, Toyoda H, Yasuda S, Tada T, et al
     Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis.
     J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13562.
     PubMed     Abstract available
     
     
     
239. YOO S, Lim TS, Lee HW, Kim JK, et al
     Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B.
     J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13560.
     PubMed     Abstract available
     
     
     
240. KANG Q, Xu J, Luo H, Tan N, et al
     Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication.
     J Viral Hepat. 2021 Jun 9. doi: 10.1111/jvh.13558.
     PubMed     Abstract available
     
     
     
241. NISHIDA Y, Imamura M, Yuji T, Morio K, et al
     Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients.
     J Viral Hepat. 2021 Jun 9. doi: 10.1111/jvh.13557.
     PubMed     Abstract available
     
     
     
242. DONG Y, Li A, Zhu S, Chen W, et al
     Biopsy-proven liver cirrhosis in young children: A 10-year cohort study.
     J Viral Hepat. 2021;28:959-963.
     PubMed     Abstract available
     
     
     
243. CHENG D, Han B, Zhang W, Wu W, et al
     Clinical effects of NTCP-inhibitor myrcludex B.
     J Viral Hepat. 2021;28:852-858.
     PubMed     Abstract available
     
     
     May 2021
244. WANG S, Fang S, Liu Y
     The 5-year cumulative incidence HCC development and treatment regimen in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment.
     J Viral Hepat. 2021 May 29. doi: 10.1111/jvh.13553.
     PubMed     Abstract available
     
     
     
245. BROWN C, Siegele M, Wright M, Cook C, et al
     Injecting network structure determines the most efficient strategy to achieve Hepatitis C elimination in people who inject drugs.
     J Viral Hepat. 2021 May 28. doi: 10.1111/jvh.13554.
     PubMed     Abstract available
     
     
     
246. RODRIGUEZ-TAJES S, Lens S, Forns X
     Reply to: Optimal hepatitis B vaccination schedule for cirrhotic patients: a still unanswered question.
     J Viral Hepat. 2021 May 28. doi: 10.1111/jvh.13555.
     PubMed     Abstract available
     
     
     
247. ARSLAN F, Franci G, Nastri BM, Pagliano P, et al
     Hepatitis B virus-induced Hepatocarcinogenesis: A Virological and Oncological Perspective.
     J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13551.
     PubMed     Abstract available
     
     
     
248. SMITH DA, Bradshaw D, Mbisa J, Manso CF, et al
     Real World SOF/VEL/VOX Retreatment Outcomes and Viral Resistance Analysis for HCV Patients with Prior Failure to DAA Therapy.
     J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13549.
     PubMed     Abstract available
     
     
     
249. OHLENDORF V, Schafer A, Christensen S, Heyne R, et al
     Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting- results from the German Hepatitis C-Registry (DHC-R).
     J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13546.
     PubMed     Abstract available
     
     
     
250. DUFFELL E, Cortez-Pinto H, Simonova M, Dalgard O, et al
     Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C.
     J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13545.
     PubMed     Abstract available
     
     
     
251. LIU PC, Chan C, Huang YH, Chen YJ, et al
     Genetic Variants Associated With Serum Alanine Aminotransferase Levels Among Patients With Hepatitis C Virus Infection: A Genome-Wide Association Study.
     J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13550.
     PubMed     Abstract available
     
     
     
252. KIM S, Powell J, Naugle J, Ricco M, et al
     Patient-Reported Experiences with Direct Acting Antiviral Therapy in an Integrated Model of Hepatitis C Care in Homeless Shelters.
     J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13544.
     PubMed     Abstract available
     
     
     
253. NANA J, Skaare K, Bosson JL, Leroy V, et al
     EASL-ALEH 2015 algorithm for the use of transient elastography in treatment-naive patients with Hepatitis B: an independent validation.
     J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13548.
     PubMed     Abstract available
     
     
     
254. MCDONALD SA, Barclay ST, Innes HA, Fraser A, et al
     Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality.
     J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13543.
     PubMed     Abstract available
     
     
     
255. COMBET C, Bhardwaj N, Hedskog C, Podlaha O, et al
     Hepatitis B Virus Genome Diversity in Adolescents: Tenofovir Disoproxil Fumarate Treatment Effect and HBeAg Seroconversion.
     J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13547.
     PubMed     Abstract available
     
     
     
256. HUANG PY, Wang JH, Hung CH, Lu SN, et al
     The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients.
     J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13528.
     PubMed     Abstract available
     
     
     
257. WOLF JM, Pereira VRZB, Simon D, Lunge VR, et al
     Temporal and geographic spreading of hepatitis B virus genotype A (HBV-A) in Brazil and the Americas.
     J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13527.
     PubMed     Abstract available
     
     
     
258. COWAN E, Hardardt J, Brandspiegel S, Eiting E, et al
     Care cascade of patients with Hepatitis C and HIV identified by Emergency Department screening.
     J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13529.
     PubMed     Abstract available
     
     
     
259. LEE J, Kim GA, Kim HJ, Cho S, et al
     Tenofovir Disoproxil Fumarate on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Failure to Preceding Treatments: A Nationwide Cohort Study.
     J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13530.
     PubMed     Abstract available
     
     
     April 2021
260. KUMADA T
     Reply to: 'Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis'.
     J Viral Hepat. 2021 Apr 28. doi: 10.1111/jvh.13514.
     PubMed    
     
     
     
261. CHEN H, Ding X, Liao G, Xia M, et al
     Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in non-cirrhotic HBeAg-positive chronic hepatitis B.
     J Viral Hepat. 2021 Apr 26. doi: 10.1111/jvh.13526.
     PubMed     Abstract available
     
     
     
262. CALVARUSO V, Petta S, Cacciola I, Cabibbo G, et al
     Liver and Cardiovascular Mortality After Hepatitis C Virus Eradication by DAA: data from RESIST-HCV Cohort.
     J Viral Hepat. 2021 Apr 25. doi: 10.1111/jvh.13523.
     PubMed     Abstract available
     
     
     
263. FIMMEL CJ, Khan MQ, Belopolsky Y, Imas P, et al
     Sustained and cumulative impact of an electronic medical record-based alert on a hepatitis C birth cohort screening program.
     J Viral Hepat. 2021 Apr 25. doi: 10.1111/jvh.13524.
     PubMed     Abstract available
     
     
     
264. HERNANDEZ C, Trujillo D, Turner CM, Sicro S, et al
     Reaching trans-women in San Francisco for efforts to eliminate hepatitis C.
     J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13521.
     PubMed     Abstract available
     
     
     
265. YU W, Ji H, Long F, Chen S, et al
     Inhibition of Hepatitis E Virus Replication by Zinc-Finger Antiviral Protein synergizes with IFN-beta.
     J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13522.
     PubMed     Abstract available
     
     
     
266. ANUGWOM C, Campbell C, Debes JD
     Assessment of subclinical effects of Hepatitis E virus infection in the United States.
     J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13519.
     PubMed     Abstract available
     
     
     
267. COOPER SL, King WC, Mogul DB, Ghany MG, et al
     Clinical Significance of Quantitative e Antigen in a Cohort of Hepatitis B Virus Infected Children and Adults in North America.
     J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13520.
     PubMed     Abstract available
     
     
     
268. MOKAYA J, Vasylyeva TI, Barnes E, Ansari MA, et al
     Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations.
     J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13525.
     PubMed     Abstract available
     
     
     
269. GOUTZAMANIS S, Spelman T, Harney B, Dietze P, et al
     Patient-reported outcomes of the Treatment and Prevention Study: A real-world community-based trial of direct-acting antivirals for hepatitis C among people who inject drugs.
     J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13516.
     PubMed     Abstract available
     
     
     
270. KAMALAPIRAT T, Yingcharoen K, Ungtrakul T, Soonklang K, et al
     Assessing Risk Scores for Predicting Hepatocellular Carcinoma in Thai Patients with Chronic Hepatitis B.
     J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13517.
     PubMed     Abstract available
     
     
     
271. SHEN DT, Han PC, Ji DZ, Chen HY, et al
     Epidemiology estimates of hepatitis D in individuals co-infected with HIV and HBV, 2002-2018: a systematic review and meta-analysis.
     J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13512.
     PubMed     Abstract available
     
     
     
272. HARTARD C, Fenaux H, Gentilhomme A, Murray JM, et al
     Variability in molecular characteristics of Hepatitis E Virus quasispecies could modify viral surface properties and transmission.
     J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13513.
     PubMed     Abstract available
     
     
     
273. WENG F
     Comment on "Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis".
     J Viral Hepat. 2021 Apr 19. doi: 10.1111/jvh.13515.
     PubMed     Abstract available
     
     
     
274. DZINGIRAI B, Katsidzira L, Matyanga CMJ, Postma MJ, et al
     Progress on the elimination of viral hepatitis in Zimbabwe: A review of the policies, strategies and challenges.
     J Viral Hepat. 2021 Apr 2. doi: 10.1111/jvh.13510.
     PubMed     Abstract available
     
     
     
275. YAO K, Liu J, Wang J, Yan X, et al
     Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the gray zone.
     J Viral Hepat. 2021 Apr 2. doi: 10.1111/jvh.13511.
     PubMed     Abstract available
     
     
     
276. ZHANG Y, Xu W, Zhu X, Li X, et al
     The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: A prospective cohort study.
     J Viral Hepat. 2021;28:592-600.
     PubMed     Abstract available
     
     
     
277. LEE TH, Chan A, Bryan W, Park L, et al
     Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort.
     J Viral Hepat. 2021;28:630-636.
     PubMed     Abstract available
     
     
     March 2021
278. PERICOT-VALVERDE I, Rennert L, Heo M, Akiyama MJ, et al
     Rates of perfect self-reported adherence to direct-acting antiviral therapy and its correlates among people who inject drugs on medications for opioid use disorder: The PREVAIL study.
     J Viral Hepat. 2021;28:548-557.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: